ISCT 2018

Montreal, Canada | May 02, 2018–May 05, 2018

Visit booth #303 at ISCT 2018 to learn more about our industry-leading cell culture media solutions designed expressly for cell therapy applications.

Discover how the expanding PRIME-XV® portfolio of cGMP media aimed to support the large-scale expansion of clinical-grade cells—including chemically-defined media (CDM) for immune cells (T and DC), and xeno-free, serum-free (XSFM) for stem cells—can support your laboratory.

Irvine Scientific will be participating in the following talk:

Thursday, May 3, 2018 3:15–3:45 PM
Product Theatre

Chemically-Defined Culture Media for Advancing Cell-Based Immunotherapy Technology
Cell-based immunotherapy applications are widely captivating today due to their clinical potential to become life-saving therapies for cancer patients. Generation of sufficient, desired cell populations is an essential task for the successful development of cell-based immunotherapies, which require an effective, scalable, and consistent ex vivo process. A suitable chemically-defined (CD), animal-component-free (ACF) cells basal media for major immune cells, such as T-cells and natural killer (NK) cells, would significantly foster the establishment of such a process. By applying spent media analysis and the quality by design (QbD) approach, we examined the effects of various key media compositions such as amino acids, vitamins, minerals, and lipids on activated human peripheral blood-derived T-cells or NK cells expansion. The results from our studies were used to develop CD, ACF basal expansion media for desired T-cell and NK cell populations that are comparable to media containing serum, and further indicate the need to develop cells- and application-specific basal media to establish an optimal production process for a desired/targeted immune cell-based therapy under CD conditions.

Jessie Ni, PhD
Chief Scientific Officer, R&D, Irvine Scientific

Products on Display:

Conference Location:
Palais des Congrès de Montréal